Research Paper Volume 16, Issue 3 pp 2090—2122
MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis
Figure 5. MAEL expression predicts the benefit from ICI-based immunotherapies over VEGFR/mTOR inhibitors in advanced/metastatic ccRCCs. (A) Heatmap illustrating MAEL expression and clinicopathological features of the JAVELIN Renal 101 cohort. (B) The associations of the cut-off value with the treatment effect in the above- and the below-cut-off groups in the training set of the JAVELIN Renal 101 cohort. (C–E) The treatment effect (avelumab plus axitinib vs. sunitinib) in the low and the high MAEL expression groups in the training set (C), the validation set (D), and the total set (E) of the JAVELIN Renal 101 cohort. (F) Heatmap illustrating MAEL expression and clinicopathological features of the CheckMate-025 cohort. (G) The associations of the cut-off value with the treatment effect in the above- and the below-cut-off groups of the CheckMate-025 cohort. (H) The treatment effect (nivolumab vs. everolimus) in the low and the high MAEL expression groups of the CheckMate-025 cohort. Abbreviations: CI=confidence interval, CR=complete response, HR=hazard ratio, IC=immune cell, ITH=intratumoral heterogeneity, NE=not evaluable, ORR=objective response rate, PD=progressive disease, PD-L1=programmed cell death-ligand 1, PR=partial response, SD=stable disease, TCGA=The Cancer Genome Atlas, TMB=tumor mutational burden.